No Data
No Data
BMO Capital Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $63
Jasper Therapeutics Analyst Ratings
BMO Capital Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $63
Express News | Jasper Therapeutics Inc - Initial Data Expected in Second Half of 2025
Express News | Jasper Therapeutics Announces First Patient Dosed in Phase 1B/2a Etesian Clinical Study of Briquilimab in Asthma
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
Unlock the Full List
Kamacho09 OP : Shoulda bought more at 15